Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Cannot have received: any anticancer therapy

Exception: adjuvant/neoadjuvant therapy permitted if completed >2 weeks before cycle 1 day 1

Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤2 weeks prior to cycle 1 day 1

Cannot have received: investigational drug

Use of an anti-cancer treatment drug or investigational drug during the last 28 days or 5 half-lives (whichever is shorter) prior to cycle 1 day 1. A minimum of 10 days between termination of prior treatment and administration of study treatment is required.

Cannot have received: investigational anti-cancer study

Participation in an investigational anti-cancer study within 3 weeks prior to Cycle 1 Day 1

Cannot have received: concurrent anticancer therapy

Exception: steroids allowed

Concurrent therapy with approved or investigational anticancer therapeutic other than steroids.